4583 Chiome Bioscience
- 103
- +3+3.00%
Chiome Bioscience News
Chiome Bioscience: Announcement of research results related to the ADLib system at Antimide Engineering & Therapeutics Asia 2024
Chiome Bioscience: Announcement of research results using our antibodies at the 39th American Society for Cancer Immunotherapy
Chiome Bioscience: Notice regarding the monthly exercise status of the 21st Stock Acquisition Rights (with exercise price amendment clause)
Chiome Bioscience: Change Report
Chiome Bioscience: Notice of a business partnership with Merck Co., Ltd. regarding antibody production contract services, etc.
Chiome Bioscience: Announcement of research results using our antibodies at ECTRIMS2024
Chiome Bioscience: Change report.
Chiome Bioscience: Announcement of research results using our antibodies at Kidney Health In Aging and Aged Societies
Chiome Bioscience: Notice Concerning Mass Exercise of the 21st Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiome Bioscience: Change Report
Chiome Bioscience: Notice Concerning Mass Exercise and Monthly Exercise Status of the 21st Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiome Bioscience: Announcement of research results using our antibodies at the 83rd Annual Meeting of the Japanese Cancer Society
Chiome Bioscience: Change report.
Chiome Bioscience: Change report.
Chiome Bioscience: Announcements of the exercise of large amounts of subscription rights (with exercise price adjustment clause) in the 21st period.
Chiome Bioscience: Report on Corporate Governance, August 14, 2024.
Chiome Bioscience: Confirmation letter
Chiome Bioscience: Interim Report - 21st period (01/01/2024 - 12/31/2024)
Chiome Bioscience: Supplementary information on the financial results for the second quarter of the period ending December 2024.
Chiome Bioscience: Non-consolidated performance for the 6 months ending on June 30th, 2024 (Japanese accounting standards).
Analysis
Price Target
No Data
No Data